NCT05588648 - Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions

Osteosarcoma

Interventions

DRUG

Vactosertib

Vactosertib is given twice a day, five days on and two days off in four-week cycles. Vactosertib is a transforming growth factor-beta (TGF-β) type 1 receptor inhibitor.

Trial Locations (3)

44106

RECRUITING

UH Rainbow Babies & Children's Hospital, Cleveland

Unknown

RECRUITING

National Cancer Center, Gyeonggi-do

RECRUITING

Korea Institute of Radiological & Medical Sciences, Seoul